If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan

Benicar Lawsuit Funding

Benicar Lawsuit Advance

Thrivest Can Help: Accelerated Access to Your Benicar Award or Legal Fee

Many of the plaintiffs involved with the Benicar Multi-District Litigation have been out of work for months, and sometimes even years. If you need money NOW for bills, house or car payments, or even everyday living expenses, Thrivest can help. Thrivest Legal Funding allows plaintiffs and attorneys to navigate through the legal life cycle with the hope of litigating cases to their fullest and appropriate value. With a simple streamlined administrative process, highly competitive pricing and terms, and a best-in-class technology, Thrivest has successfully funded tens of thousand of advances since its inception in 2009. Please call one of our friendly legal funding specialists at 888-697-7352 or complete our quick application online HERE.

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following: Benicar — olmesartan... READ MORE.

Benicar Lawsuit Settlement (Update)

If you read our initial Benicar Lawsuit Settlement article, you know that Benicar reached a $300 million settlement a little over a year ago. Since then, we have learned that there are several drugs, containing the active ingredient olmesartan medoxomil, that were sold under different brand names. Those drugs include the following:

  • Benicar — olmesartan medoxomil
  • Benicar HCT — olmesartan medoxomil + hydroclorothiazide
  • Azor — olmesartan medoxomil + amlodipine
  • Tribenzor — olmesaratan medoxomil + hydroclorothiazide + amlodipine
  • Olmetec — olmesartan medoxomil sold in Europe and Canada

History of Benicar Lawsuits

Unfortunately, this is not the first time Taiichi Sankyo has been in legal trouble over Benicar. The global pharmaceutical company, with U.S. headquarters in New Jersey, had to pay $40 million to the United States Department of Justice to settle an allegation that the company made illegal payments to doctors in return for prescribing drugs to patients between 2005 and 2011.

Benicar Settles for $300 Million

On August 1, 2017, Daiichi Sankyo reached a $300 million settlement to resolve lawsuits filed by more than 2,300 patients that developed intestinal injuries while taking Benicar. The lawsuits, which were consolidated into a Multi-District Litigation (MDL) in the state of New Jersey in March of 2015, allege that the product causes serious gastrointestinal injuries and users were inadequately warned about the risk of said injuries. The lawsuit further alleges that adequate testing was not performed on Benicar and similar drugs, resulting in a defective, unsafe and inherently dangerous product. The case documents can be seen below:

Benicar Lawsuit Loan